INmune Bio, Inc. (NASDAQ:INMB – Get Free Report) was the recipient of some unusual options trading activity on Friday. Traders bought 3,375 put options on the stock. This represents an increase of approximately 101% compared to the typical daily volume of 1,681 put options.
Hedge Funds Weigh In On INmune Bio
A number of hedge funds have recently added to or reduced their stakes in INMB. Quarry LP bought a new stake in shares of INmune Bio during the first quarter valued at about $48,000. Wells Fargo & Company MN increased its stake in INmune Bio by 51.0% in the 4th quarter. Wells Fargo & Company MN now owns 6,377 shares of the company’s stock worth $30,000 after purchasing an additional 2,155 shares in the last quarter. Beacon Pointe Advisors LLC purchased a new position in INmune Bio in the 4th quarter worth about $48,000. JPMorgan Chase & Co. grew its stake in INmune Bio by 93.0% during the 4th quarter. JPMorgan Chase & Co. now owns 11,335 shares of the company’s stock valued at $53,000 after acquiring an additional 5,461 shares in the last quarter. Finally, Focus Partners Advisor Solutions LLC purchased a new position in INmune Bio during the 1st quarter valued at about $91,000. Institutional investors and hedge funds own 12.72% of the company’s stock.
INmune Bio Stock Down 11.9%
INMB opened at $6.38 on Friday. The firm has a market capitalization of $146.61 million, a P/E ratio of -3.31 and a beta of 1.55. The firm’s 50 day moving average is $7.52 and its 200-day moving average is $7.28. INmune Bio has a 52-week low of $4.32 and a 52-week high of $10.50.
About INmune Bio
INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.
Read More
- Five stocks we like better than INmune Bio
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- New All-Time Highs Coming for Broadcom? Wall Street Says Yes
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- Overheated Market? Analysts Watch These Red Flags
- Differences Between Momentum Investing and Long Term Investing
- 3 Reasons AMD Could Be the Hottest Stock of the Summer
Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.